Defence Therapeutics Inc. (OTCMKTS:DTCFF) Sees Large Increase in Short Interest

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 4,100 shares, a growth of 1,266.7% from the January 15th total of 300 shares. Based on an average daily volume of 64,900 shares, the short-interest ratio is presently 0.1 days.

Defence Therapeutics Price Performance

Shares of OTCMKTS DTCFF remained flat at $0.78 during trading on Wednesday. The stock has a 50-day moving average price of $0.48 and a 200 day moving average price of $0.46. Defence Therapeutics has a 1-year low of $0.27 and a 1-year high of $1.49.

About Defence Therapeutics

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.